On behalf of IFARA, Fred Schaich spoke with Zeda Rosenberg, Sc.D., about the final trial results of a vaginal ring that prevents HIV, which were presented at this year's International AIDS Conference. The epivirine ring was shown to be very safe. While its overall effectiveness was modest, efficacy improved markedly with actual use of the device. Near perfect use lowered the risk of acquiring HIV by 80% or more. Usage of the vaginal ring was determined by measuring remaining drug levels in returned devices. However, this did not account for instances when, for example, women removed the ring while menstruating and not having sex, Rosenberg cautioned. An open-label extension to this study is trying to determine when and whether women actually use the device and why they might not do so.
Another upcoming clinical study among very young women (15-17 and 18-21 years old) will compare the epivirine ring with oral pre-exposure prophylaxis to see how these forms of HIV prevention could be rolled out for these age groups. A vaginal ring that combines a contraceptive with epivirine is also in development.
Watch the video to learn more:
About the panelist:
Zeda F. Rosenberg, Sc.D., International Partnership for Microbicides
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.